Relmada Therapeutics Plunges 10.99% on Earnings Report

On April 25, 2025, Relmada Therapeutics experienced a significant drop of 10.99% in pre-market trading, marking a notable decline in its stock performance.

Relmada Therapeutics has seen a series of dramatic fluctuations in its stock price over the past few days. The company reported a narrowed net loss of $0.62 per share in Q4 2024, compared to $0.84 in Q4 2023. This financial improvement contributed to a 4.03% rise in aftermarket trading, reflecting investor optimism about the company's financial health.

In a Wednesday session, the stock price of Relmada Therapeutics experienced a significant surge of 29.84%, reaching $0.49. This surge indicated positive momentum and investor confidence in the company's prospects. However, the stock later faced a decline during the after-hours session, with an additional 11.61% decrease following an earlier 82.54% drop.

Relmada Therapeutics also saw a 33.99% increase in its stock price due to investor focus driven by board shakeups and biotech financings. These developments highlighted the company's strategic moves and financial maneuvers, which attracted investor attention and contributed to the stock's volatility.